Eye On Five

pSivida Set to File 3-year Durasert NDA pSivida Corp. this month expects to file a New Drug Application with the Food and Drug Administration for…

FDA Shoots Down Ocular Therapeutix’s Dextenza NDA The Food and Drug Administration (FDA) denied approval of Ocular Therapeutix’s resubmitted New Drug Application (NDA) for its Dextenza…

Novartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared…

Alcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens…

FDA Green Lights Allergan’s Tear Neurostimulator Allergan has been granted marketing authorization from the FDA for its TrueTear Intranasal Tear Neurostimulator. This is the only FDA-approved…

Ora Retained to Develop Cannabinoids for Eye Disease Ora Inc., a global contract research organization that specializes in ophthalmology, took the plunge into medical marijuana…

Envisia Candidate Achieves Endpoint for IOP Lowering Envisia Therapeutics released Phase II results showing that its ENV515 candidate (travoprost XR) achieved clinically meaningful intraocular pressure…

Sustained-Release Eylea Focus of Collaboration Ocular Therapeutix Inc. and Regeneron entered into a collaboration agreement to develop a sustained-release formulation of Regeneron’s Eylea (aflibercept), currently…

Johnson & Johnson Moves to Buy AMO The evolution of the ophthalmology sector continued with this month’s news that Johnson & Johnson Vision Care would…